FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 357:1967-1968 November 8, 2007 Number 19 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Schmidt, B. PubMed Citation

It was recognized more than three decades ago¹ that methylxanthines can reduce the frequency of apneic episodes in premature infants. Since that time, methylxanthines have become part of the routine clinical management of apnea of prematurity, with caffeine the treatment of choice because of its long half-life in the neonate.² However, there has been ongoing concern, and a lack of good data, about potential long-term risks. In particular, caffeine can decrease cerebral blood flow in adults (when present at levels that are probably higher than the doses recommended for therapeutic use in babies)³ and can inhibit adenosine receptors,⁴ possibly compromising . . . [Full Text of this Article]

Source Information

From the Department of Pediatrics, Division of Neonatal and Developmental Medicine, Stanford University School of Medicine, Stanford, CA.

This article has been cited by other articles:

• (2007). Efficacy and Safety of Caffeine for Apnea of Prematurity. JWatch Pediatrics 2007: 1-1 [Full Text]